The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) to digital diagnostics company Ellume’s at-home Covid-19 viral antigen test.
Developed with $30m contract and technical support from the National Institutes of Health (NIH)’s Rapid Acceleration of Diagnostics (RADx) Initiative, the Ellume Covid-19 Home Test will be available without a prescription for use at home.
Go deeper with GlobalData
It can be used for detecting active Covid-19 in adults and children aged two years or above with or without symptoms.
Ellume founder and CEO Dr Sean Parsons said: “As Covid-19 case numbers hit record highs, the world needs access to fast, affordable, easy-to-use home testing.
“Ellume’s Covid-19 Home Test delivers this important first line of defence – it can be widely available without the need for a prescription, enabling the US to respond to the pandemic in its most urgent stage.”
For the test, the sample is collected using a mid-turbinate nasal swab.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe sample is then inserted into a single-use cartridge that delivers results in 15 minutes.
In addition, the at-home test analyser connects to the user’s smartphone via Bluetooth. It pairs with an app that gives step-by-step guidelines and displays results.
The test costs approximately $30. With it, users can share real-time results with healthcare specialists, employers, and schools.
The company expects to scale up manufacturing to supply millions of home tests a month next year.
In data submitted to the FDA from a clinical study on 198 subjects aged two to 82 years, the Ellume Covid-19 Home Test showed 96% accuracy with an overall sensitivity of 95% and specificity of 97% versus an emergency use-authorised RT-PCR laboratory test.
Furthermore, the test showed a sensitivity of 96% and specificity of 100% in people with symptoms and sensitivity of 91% and specificity of 96% in asymptomatic people.
